Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland flag Switzerland · Delayed Price · Currency is CHF
51.60
+0.40 (0.78%)
At close: Dec 5, 2025

Basilea Pharmaceutica AG Ratios and Metrics

Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
634501423546485574
Upgrade
Market Cap Growth
31.59%18.52%-22.52%12.62%-15.59%14.12%
Upgrade
Enterprise Value
602551505636551662
Upgrade
Last Close Price
51.6041.3535.3045.8040.9253.15
Upgrade
PE Ratio
9.436.4640.4744.94--
Upgrade
Forward PE
13.5310.6315.1798.35--
Upgrade
PS Ratio
2.682.402.683.693.274.50
Upgrade
PB Ratio
6.156.19-42.28-26.35-8.27-5.63
Upgrade
P/TBV Ratio
6.176.22----
Upgrade
P/FCF Ratio
8.146.9031.48139.32--
Upgrade
P/OCF Ratio
7.986.7429.6977.36--
Upgrade
EV/Sales Ratio
2.552.643.204.313.725.19
Upgrade
EV/EBITDA Ratio
7.518.7221.7829.31154.82-
Upgrade
EV/EBIT Ratio
7.878.9323.0530.58183.33-
Upgrade
EV/FCF Ratio
7.737.5837.59162.43--
Upgrade
Debt / Equity Ratio
0.941.38-12.86-9.03-3.74-2.37
Upgrade
Debt / EBITDA Ratio
1.211.715.057.7641.61-
Upgrade
Debt / FCF Ratio
1.241.549.5747.76--
Upgrade
Asset Turnover
1.080.970.800.630.620.57
Upgrade
Inventory Turnover
4.693.994.134.185.336.11
Upgrade
Quick Ratio
5.403.932.481.961.223.87
Upgrade
Current Ratio
6.324.853.202.341.384.46
Upgrade
Return on Equity (ROE)
121.15%218.58%----
Upgrade
Return on Assets (ROA)
21.88%17.89%6.95%5.56%0.79%-5.93%
Upgrade
Return on Capital (ROIC)
29.07%24.78%9.61%7.96%1.25%-10.88%
Upgrade
Return on Capital Employed (ROCE)
35.70%29.10%17.40%14.30%4.10%-11.90%
Upgrade
Earnings Yield
11.46%15.48%2.47%2.23%-1.41%-2.56%
Upgrade
FCF Yield
12.29%14.50%3.18%0.72%-6.73%-9.74%
Upgrade
Buyback Yield / Dilution
-15.14%-14.10%-1.67%-2.24%-13.62%4.41%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.